1. The answer is d.

Guidelines recommend that erythropoietin alfa be given in patients being treated with myelosuppressive chemotherapy with noncurative intent and who are mildly symptomatic. Although results may be seen in 2 weeks, an interval of 2–6 weeks may occur between the time of a dose adjustment and significant change in hemoglobin, which is the time required for erythropoiesis and the red blood cell half-life. Patients with uncontrolled hypertension should not be treated with erythropoietin alfa. Erythropoietin-stimulating agents have also been found to pose an increased risk for thrombosis in patients with cancer. CNPP, Pages 509–510, 702–704; CSM, Page 290.

2. The answer is d.

Infection and sepsis ...

Get Oncology Nursing Review, 6th Edition now with O’Reilly online learning.

O’Reilly members experience live online training, plus books, videos, and digital content from 200+ publishers.